AP829A - Novel hormonal medicaments and use thereof correcting oestrogen deficiencies. - Google Patents
Novel hormonal medicaments and use thereof correcting oestrogen deficiencies. Download PDFInfo
- Publication number
- AP829A AP829A APAP/P/1997/000979A AP9700979A AP829A AP 829 A AP829 A AP 829A AP 9700979 A AP9700979 A AP 9700979A AP 829 A AP829 A AP 829A
- Authority
- AP
- ARIPO
- Prior art keywords
- oestrogen
- group
- oestradiol
- oestro
- placebo
- Prior art date
Links
- 206010030247 Oestrogen deficiency Diseases 0.000 title claims description 4
- 239000003814 drug Substances 0.000 title description 3
- 230000003054 hormonal effect Effects 0.000 title description 2
- 239000000262 estrogen Substances 0.000 claims abstract description 10
- 239000000583 progesterone congener Substances 0.000 claims abstract description 8
- 239000000902 placebo Substances 0.000 claims description 33
- 229940068196 placebo Drugs 0.000 claims description 33
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 27
- 229960004190 nomegestrol acetate Drugs 0.000 claims description 26
- IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 claims description 26
- 229930182833 estradiol Natural products 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 14
- 229960005309 estradiol Drugs 0.000 claims description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001076 estrogenic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 2
- 230000006835 compression Effects 0.000 claims 2
- 238000007906 compression Methods 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 239000003701 inert diluent Substances 0.000 claims 1
- 229960004911 nomegestrol Drugs 0.000 claims 1
- KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 claims 1
- 230000009245 menopause Effects 0.000 abstract description 6
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 3
- 238000002512 chemotherapy Methods 0.000 abstract description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- 206010060800 Hot flush Diseases 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000032843 Hemorrhage Diseases 0.000 description 6
- 230000000740 bleeding effect Effects 0.000 description 6
- 229940109239 creatinine Drugs 0.000 description 6
- 210000004696 endometrium Anatomy 0.000 description 6
- 208000006662 Mastodynia Diseases 0.000 description 5
- 206010006298 Breast pain Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 210000000481 breast Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000002559 palpation Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108010071619 Apolipoproteins Proteins 0.000 description 3
- 102000007592 Apolipoproteins Human genes 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 206010027514 Metrorrhagia Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000004882 diastolic arterial blood pressure Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 230000004873 systolic arterial blood pressure Effects 0.000 description 3
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010049003 Fibrinogen Proteins 0.000 description 2
- 102000008946 Fibrinogen Human genes 0.000 description 2
- LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 229940012952 fibrinogen Drugs 0.000 description 2
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 description 1
- 108010059886 Apolipoprotein A-I Proteins 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000029301 Protein S Human genes 0.000 description 1
- 108010066124 Protein S Proteins 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 102000036124 hormone binding proteins Human genes 0.000 description 1
- 108091011044 hormone binding proteins Proteins 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9509364A FR2737411B1 (fr) | 1995-08-01 | 1995-08-01 | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques |
| PCT/IB1996/000754 WO1997004784A1 (fr) | 1995-08-01 | 1996-07-29 | Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9700979A0 AP9700979A0 (en) | 1997-07-31 |
| AP829A true AP829A (en) | 2000-05-03 |
Family
ID=9481610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1997/000979A AP829A (en) | 1995-08-01 | 1996-07-29 | Novel hormonal medicaments and use thereof correcting oestrogen deficiencies. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US5891867A (es) |
| EP (1) | EP0783310B1 (es) |
| JP (1) | JPH10507207A (es) |
| KR (1) | KR100450649B1 (es) |
| CN (1) | CN1138547C (es) |
| AP (1) | AP829A (es) |
| AR (1) | AR004502A1 (es) |
| AT (1) | ATE225659T1 (es) |
| AU (1) | AU722355B2 (es) |
| BR (1) | BR9606549A (es) |
| CA (1) | CA2201368C (es) |
| CZ (1) | CZ289706B6 (es) |
| DE (1) | DE69624214T2 (es) |
| DK (1) | DK0783310T3 (es) |
| DZ (1) | DZ2078A1 (es) |
| ES (1) | ES2184880T3 (es) |
| FR (1) | FR2737411B1 (es) |
| HU (1) | HU229843B1 (es) |
| IL (1) | IL120558A (es) |
| MA (1) | MA23946A1 (es) |
| MX (1) | MX9702381A (es) |
| MY (1) | MY117307A (es) |
| NO (1) | NO312996B1 (es) |
| OA (1) | OA10411A (es) |
| PT (1) | PT783310E (es) |
| RU (1) | RU2188641C2 (es) |
| TN (1) | TNSN96101A1 (es) |
| TW (1) | TW473390B (es) |
| WO (1) | WO1997004784A1 (es) |
| ZA (1) | ZA966545B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2754179B1 (fr) * | 1996-10-08 | 1998-12-24 | Theramex | Nouvelle composition hormononale et son utilisation |
| WO2001030355A1 (fr) * | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation |
| US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
| WO2001030356A1 (fr) | 1999-10-25 | 2001-05-03 | Laboratoire Theramex | Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation |
| US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
| FR2814074B1 (fr) * | 2000-09-15 | 2003-03-07 | Theramex | Nouvelles compositions estro-progestatives topiques a effet systemique |
| US20020151732A1 (en) * | 2001-01-05 | 2002-10-17 | Claes Ohlsson | Estrogen receptors |
| US20030004145A1 (en) * | 2001-05-16 | 2003-01-02 | Leonard Thomas W. | Treatment of conditions relating to hormone deficiencies by administration of progestins |
| EP2305230B1 (en) * | 2001-12-05 | 2015-11-04 | Teva Women's Health, Inc. | Oral contraceptives to prevent pregnancy |
| US7008979B2 (en) * | 2002-04-30 | 2006-03-07 | Hydromer, Inc. | Coating composition for multiple hydrophilic applications |
| JP2007534622A (ja) * | 2003-07-16 | 2007-11-29 | デュラメド ファーマシューティカルズ インコーポレーティッド | 連続的エストロゲン投与での避妊薬療法を利用するホルモン処置の方法 |
| US20070111975A1 (en) | 2004-10-07 | 2007-05-17 | Duramed Pharmaceuticals, Inc. | Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens |
| US8022053B2 (en) * | 2004-11-02 | 2011-09-20 | Bayer Schering Pharma Aktiengesellschaft | Oral solid dosage forms containing a low dose of estradiol |
| AR065816A1 (es) * | 2007-03-26 | 2009-07-01 | Theramex | Regimen anticonceptivo oral |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3229612A1 (de) * | 1981-08-10 | 1983-02-24 | Syntex (U.S.A.) Inc., 94304 Palo Alto, Calif. | Pharmazeutische packung |
| WO1994006437A1 (fr) * | 1992-09-21 | 1994-03-31 | Laboratoire Theramex S.A. | Implants sous-cutanes a base de derives de nomegestrol |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4826831A (en) * | 1983-08-05 | 1989-05-02 | Pre Jay Holdings Limited | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens |
| US4870066A (en) * | 1986-08-11 | 1989-09-26 | The University Of Kentucky Research Foundation | Method and composition for safely delaying parturition and synchronizing farrowing in swine |
| DE69132061D1 (de) * | 1990-09-28 | 2000-04-20 | I F L O S A S Di Giorgio E Ald | Kontrazeptives und Menstruationszyklus regulierendes Präparat mit onkostatischen Eigenschaften |
-
1995
- 1995-08-01 FR FR9509364A patent/FR2737411B1/fr not_active Expired - Fee Related
-
1996
- 1996-07-22 MA MA24321A patent/MA23946A1/fr unknown
- 1996-07-26 MY MYPI96003099A patent/MY117307A/en unknown
- 1996-07-29 AP APAP/P/1997/000979A patent/AP829A/en active
- 1996-07-29 JP JP9507406A patent/JPH10507207A/ja not_active Ceased
- 1996-07-29 BR BR9606549A patent/BR9606549A/pt not_active Application Discontinuation
- 1996-07-29 ES ES96923018T patent/ES2184880T3/es not_active Expired - Lifetime
- 1996-07-29 EP EP96923018A patent/EP0783310B1/fr not_active Expired - Lifetime
- 1996-07-29 AT AT96923018T patent/ATE225659T1/de active
- 1996-07-29 HU HU9900612A patent/HU229843B1/hu unknown
- 1996-07-29 AU AU63674/96A patent/AU722355B2/en not_active Expired
- 1996-07-29 IL IL12055896A patent/IL120558A/en not_active IP Right Cessation
- 1996-07-29 CN CNB96191100XA patent/CN1138547C/zh not_active Expired - Lifetime
- 1996-07-29 KR KR1019970702125A patent/KR100450649B1/ko not_active Expired - Lifetime
- 1996-07-29 CZ CZ1997967A patent/CZ289706B6/cs not_active IP Right Cessation
- 1996-07-29 MX MX9702381A patent/MX9702381A/es active IP Right Grant
- 1996-07-29 US US08/817,329 patent/US5891867A/en not_active Expired - Lifetime
- 1996-07-29 CA CA2201368A patent/CA2201368C/fr not_active Expired - Lifetime
- 1996-07-29 WO PCT/IB1996/000754 patent/WO1997004784A1/fr not_active Ceased
- 1996-07-29 DE DE69624214T patent/DE69624214T2/de not_active Expired - Lifetime
- 1996-07-29 DK DK96923018T patent/DK0783310T3/da active
- 1996-07-29 RU RU97108279/14A patent/RU2188641C2/ru active
- 1996-07-29 PT PT96923018T patent/PT783310E/pt unknown
- 1996-07-30 DZ DZ960122A patent/DZ2078A1/fr active
- 1996-07-31 AR ARP960103818A patent/AR004502A1/es not_active Application Discontinuation
- 1996-08-01 TN TNTNSN96101A patent/TNSN96101A1/fr unknown
- 1996-08-01 ZA ZA966545A patent/ZA966545B/xx unknown
- 1996-09-24 TW TW085111673A patent/TW473390B/zh not_active IP Right Cessation
-
1997
- 1997-03-26 NO NO19971449A patent/NO312996B1/no not_active IP Right Cessation
- 1997-04-01 OA OA60985A patent/OA10411A/fr unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3229612A1 (de) * | 1981-08-10 | 1983-02-24 | Syntex (U.S.A.) Inc., 94304 Palo Alto, Calif. | Pharmazeutische packung |
| WO1994006437A1 (fr) * | 1992-09-21 | 1994-03-31 | Laboratoire Theramex S.A. | Implants sous-cutanes a base de derives de nomegestrol |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP829A (en) | Novel hormonal medicaments and use thereof correcting oestrogen deficiencies. | |
| CN1159917A (zh) | 基于天然雌激素的多相避孕制剂 | |
| HK1210708A1 (en) | Hormonal composition consisting of an oestrogen compound and of a progestational compound | |
| KR100623788B1 (ko) | 호르몬 조성물 및 이의 용도 | |
| RU2258512C2 (ru) | Противозачаточное лекарственное средство на основе гестагена и эстрогена и способ его получения | |
| JPH01211527A (ja) | 更年期障害及びオステオポローシスの治療用医薬投与ユニット | |
| JP2001523639A (ja) | プロゲストゲン−抗プロゲストゲンレジメン | |
| AU771059B2 (en) | Use of antiprogestagens in combined therapy | |
| JPH08508502A (ja) | 骨粗しょう症の治療方法および治療用組成物 | |
| CN116570593A (zh) | 一种防止卵巢早衰的药物及其用途 | |
| KR20030043797A (ko) | 호르몬 조성물 | |
| MXPA99003291A (es) | Composicion hormonal constituida de un compuesto estrogeno y de un compuesto progestacional | |
| HK1024420A (en) | Hormonal composition consisting of an oestrogen compound and of a progestational compound | |
| HK1121685A (en) | Hormonal composition consisting of an estrogen compound and of a progestational compound | |
| HK1005227B (zh) | 一种用於矫正绝经妇女雌激素不足的激素药用组合物 |